Search

Mirabegron (Betmiga™), a β3-adrenergic receptor agonist, is a useful option for the treatment of overactive bladder syndrome. In clinical trials in this patient population, oral mirabegron 50 mg once daily significantly reduced incontinence and micturition episodes, consistently reduced urgency episodes and increased the volume of urine voided per micturition, and was associated with improvements in health-related quality of life and treatment satisfaction. Mirabegron is generally well tolerated and is associated with less dry mouth than extended-release tolterodine.

Once-daily administration of the rotigotine transdermal patch (Neupro®) is effective in treating patients with early Parkinson’s disease (as monotherapy), advanced Parkinson’s disease (in combination with levodopa), inadequate morning motor control despite antiparkinsonian treatment (mostly in combination with levodopa), and moderate to severe idiopathic restless legs syndrome. Rotigotine is generally well tolerated, with the most common treatment-emergent adverse events being application-site reactions, gastrointestinal disturbances, somnolence and headache.

The CD20 monoclonal antibody ofatumumab is effective in the treatment of patients with chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab. Although adverse events such as infection and neutropenia are common, intravenous ofatumumab has an acceptable tolerability profile in this heavily pre-treated population.